|
U3A
|
BAO_0002683 |
|
|
assay screening campaign stage
|
BAO_0000029 |
|
|
LYMP2-026
|
BAO_0002684 |
|
|
assay quality assessment method
|
BAO_0000028 |
|
|
MV-4-11
|
BAO_0002685 |
|
|
assay provider
|
BAO_0000027 |
|
|
researcher role
|
BAO_0002900 |
|
|
LYMP2-007
|
BAO_0002686 |
|
|
LYMP2-006
|
BAO_0002687 |
|
|
hepatitis C virus nonstructural protein 5A inhibitor
|
CHEBI_85185 |
|
|
WAGR syndrome
|
DOID_14515 |
|
|
chromosomal deletion syndrome
|
DOID_0060388 |
|
|
enzyme activator
|
CHEBI_195252 |
|
|
activator
|
CHEBI_195251 |
|
|
LYMP2-004
|
BAO_0002699 |
|
|
radiolabeled
|
BAO_0000036 |
|
|
assay method component
|
BAO_0002753 |
|
|
Kd
|
BAO_0000034 |
|
|
Bmax
|
BAO_0000033 |
|
|
secondary assay
|
BAO_0000032 |
|
